Ala Lisok
Impact in
- Oncology top 2%
- Cancer Immunotherapy and Biomarkers
- Peptidase Inhibition and Analysis
- Cancer Cells and Metastasis
-
- Radiopharmaceutical Chemistry and Applications
- Medical Imaging Techniques and Applications
Papers in
-
- Radiopharmaceutical Chemistry and Applications 18
- Monoclonal and Polyclonal Antibodies Research 6
- Oncology 21
- Cancer Immunotherapy and Biomarkers 7
- Chemokine receptors and signaling 5
- Peptidase Inhibition and Analysis 5
- Co-authors
- Martin G. Pomper (39 shared papers)Sridhar Nimmagadda (18 shared papers)Farhad Vesuna (4 shared papers)Venu Raman (4 shared papers)Samit Chatterjee (12 shared papers)Bryan L. Wharram (10 shared papers)Ronnie C. Mease (15 shared papers)Wojciech G. Lesniak (13 shared papers)
- Journals
- Journal of Nuclear Medicine (5 papers)Bioconjugate Chemistry (4 papers)Molecular Pharmaceutics (4 papers)Oncotarget (3 papers)Oncogene (2 papers)
- Partner nations
- United StatesChinaPoland
In The Last Decade
Ala Lisok
44 papers receiving 2.1k citations
Peers
Comparison fields: 5 of 92
- Oncology 951
- Radiology, Nuclear Medicine and Imaging 784
- Pulmonary and Respiratory Medicine 452
- Cancer Research 187
- Immunology 272
Countries citing papers authored by Ala Lisok
This map shows the geographic impact of Ala Lisok's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ala Lisok with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ala Lisok more than expected).
Fields of papers citing papers by Ala Lisok
This network shows the impact of papers produced by Ala Lisok. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ala Lisok. The network helps show where Ala Lisok may publish in the future.
Co-authors
The 25 scholars most cited alongside Ala Lisok, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 44 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2009 | 201 | |
| 2 | 2008 | 193 | |
| 3 | 2016 | 142 | |
| 4 | 2016 | 135 | |
| 5 | 2011 | 134 | |
| 6 | 2018 | 124 | |
| 7 | 2018 | 109 | |
| 8 | 2019 | 74 | |
| 9 | 2019 | 66 | |
| 10 | 2017 | 65 | |
| 11 | 2016 | 63 | |
| 12 | 2015 | 57 | |
| 13 | 2019 | 55 | |
| 14 | 2011 | 51 | |
| 15 | 2016 | 47 | |
| 16 | 2018 | 47 | |
| 17 | 2014 | 46 | |
| 18 | 2015 | 41 | |
| 19 | 2019 | 40 | |
| 20 | 2021 | 39 |
About Ala Lisok
Ala Lisok is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology, Molecular Biology, Pulmonary and Respiratory Medicine and Biomedical Engineering, having authored 44 papers that have together received 2.2k indexed citations. Recurring topics across this work include Radiopharmaceutical Chemistry and Applications (18 papers), Prostate Cancer Treatment and Research (9 papers), Cancer Immunotherapy and Biomarkers (7 papers), Nanoplatforms for cancer theranostics (7 papers), Monoclonal and Polyclonal Antibodies Research (6 papers), Immunotherapy and Immune Responses (5 papers), Chemokine receptors and signaling (5 papers) and Peptidase Inhibition and Analysis (5 papers). The work is most often cited by research in Oncology (951 citations), Radiology, Nuclear Medicine and Imaging (784 citations), Pulmonary and Respiratory Medicine (452 citations), Cancer Research (187 citations) and Immunology (272 citations). Ala Lisok has collaborated with scholars based in United States, China and Poland. Frequent co-authors include Martin G. Pomper, Sridhar Nimmagadda, Farhad Vesuna, Venu Raman, Samit Chatterjee, Bryan L. Wharram, Ronnie C. Mease, Wojciech G. Lesniak, J. Brian Kimble and Sangeeta Ray Banerjee. Their work appears in journals such as Journal of Nuclear Medicine, Bioconjugate Chemistry, Molecular Pharmaceutics, Oncotarget and Oncogene.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.